Kraig Biocraft Laboratories Inc IPO: How to Buy Kraig Biocraft Laboratories Inc Stock When It Goes Public

Kraig Biocraft Laboratories Inc, a Lansing, Michigan-based biotechnology company, has applied for listing on the Nasdaq Capital Market under the symbol "KBLB." The company is currently traded on the Over-the-Counter Markets under the same symbol.

What we know about the Kraig Biocraft Laboratories Inc IPO

Kraig Biocraft Laboratories Inc filed a registration form with the US Securities and Exchange Commission (SEC) to go public on the Nasdaq Capital Market under the ticker symbol KBLB. Not yet an official IPO, this is one of the first steps of taking a private company public.

The exact IPO date has not been announced. There's no news yet about how much the stock will cost when it goes public. We'll update this page with more information as it becomes available.

How to buy Kraig Biocraft Laboratories Inc stock when it starts trading

Once Kraig Biocraft Laboratories Inc goes public, you'll need a brokerage account to invest. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.

Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
Open your brokerage account. Complete an application with your details.
Confirm your payment details. Fund your account.
Research the stock. Find the stock by name or ticker symbol – KBLB – and research it before deciding if it's a good investment for you.
Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.

Finder's picks for buying Kraig Biocraft Laboratories Inc stock when it goes public

Go to site

$0 commission trading
Instant withdrawals with a 1.75% fee
Supports 250+ cryptocurrencies
High-yield account earns up to 4.40% APY

Disclaimer

Go to site

Trade options, futures, options on futures, stocks, ETFs
$0 commission to close options
Pro-grade platform and risk analysis tools

Go to site

Trade $0 commission stocks, ETFs, and options with as little as $1
After-hours trading available
Earn 4.5% interest on uninvested cash with Gold
24/7 customer support

How do similar companies perform?

It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. Looking at the performance of similar companies can help you decide if now is a good time to buy Kraig Biocraft Laboratories Inc stock.

See how the following stocks are performing, and view details like market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield.

Company summary
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Historical performance
Stock information
- Market capitalization: $99883200
- PEG ratio: 0
- Dividend yield: N/A%
Get more detailed information and learn how to buy EDIT.US stock
Company summary
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Historical performance
Stock information
- Market capitalization: $1227280512
- PEG ratio: -0.0969
- Dividend yield: N/A%
Get more detailed information and learn how to buy NTLA.US stock
Company summary
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Historical performance
Stock information
- Market capitalization: $3494372352
- PEG ratio: -0.2142
- Dividend yield: N/A%
Get more detailed information and learn how to buy CRSP.US stock

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

1 - 10 of 10

Product USFST	Finder Score	Available asset types	Stock trade fee	Minimum deposit	Cash sweep APY	Signup bonus
Tastytrade	Finder score 8.8 Great	Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills	$0	$0	N/A	Get $50-$5,000	Go to site View details	loading Fetching your data...
Robinhood	Finder score 9 Excellent	Stocks, Options, ETFs, Cryptocurrency	$0	$0	4.5%	Get a free stock	Go to site View details	loading Fetching your data...
SoFi Invest®	Finder score 8.2 Great	Stocks, Options, Mutual funds, ETFs, Alternatives	$0	$0	0.02%	Get up to $1,000 in stock	Go to site View details	loading Fetching your data...
OPTO	Finder score 6.2 Standard	Stocks, ETFs	$0	$0	N/A	Earn up to $300	Go to site View details	loading Fetching your data...
eToro	Finder score 8 Great	Stocks, Options, ETFs, Cryptocurrency	$0	$0	4.9%	FINDER EXCLUSIVE: Get a guaranteed $15 bonus and $10 in free crypto	Go to site View details	loading Fetching your data...
Public.com	Finder score 8.6 Great	Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account	$0	$0	4.35%	Get up to $10,000 and transfer fees covered	Go to site View details	loading Fetching your data...
Stash	Finder score 7.4 Great	Stocks, ETFs	$0	$0	0.1%	Get $10 when you sign up and deposit $5	Go to site View details	loading Fetching your data...
Wealthfront	Finder score 9 Excellent	Stocks, ETFs	$0	$500	4.00%	Get $50	Go to site View details	loading Fetching your data...
Zacks Trade	Finder score 7.6 Great	Stocks, Bonds, Mutual funds, ETFs, CDs	$0.01	$250	2.83%	Get up to $500	Go to site View details	loading Fetching your data...
M1 Finance	Finder score 8.2 Great	Stocks, ETFs, Cryptocurrency	$0	$100	4.00%	N/A	Go to site View details	loading Fetching your data...

loading

What is the Finder Score?

The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.

We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.

Read the full Finder Score breakdown

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

More on investing

How to buy FAANG stocks

Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.

Read more…

How to buy soccer stocks

A simple guide to buying stocks in your favorite European soccer team.

Read more…

Inflation stocks

Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.

Read more…

Thank you for your feedback!

More resources on Finder

How to buy BlockFi stock when it goes public How to buy Solera Holdings stock when it goes public

More guides on Finder

MoneyKey Loans Review: Fast But Expensive Way to Borrow
A review of MoneyKey, a lender that offers installment loans and lines of credit up to $3,500 to borrowers with poor credit.
APY vs. Interest Rate: The Difference Matters
APY stands for “annual percentage yield” and factors in compound interest. See why the difference between APY and interest matters so much.
What Is an Interest-Bearing Account?
Interest-bearing accounts passively grow your money. Compare common types of accounts that earn interest and find the best one for you.
How Much Should You Keep in Your Checking Account?
Try to keep enough money in your checking account to cover monthly expenses, plus a small cushion. Read more tips here.
Chime Secured Credit Builder Visa® Credit Card Review
The Chime Credit Builder Card can help you build credit without charging interest and doesn’t require a deposit or monthly fee.
5 Apps Like Ualett for Gig Workers
Explore cash advance apps like Ualett, perfect for gig workers looking for quick funding, budgeting support and flexible borrowing options.
CashUSA: Fast But Flawed Loan Connection Up to $10K
A review of CashUSA, a loan connection service that may match you with lenders offering loans up to $10,000.
How to Earn Money Playing Games
Explore different ways you could earn money playing games with GPT apps, Twitch streaming, esports competitions, and trading cards.
Highest Paying Online Surveys
Compare highly rated and legit survey sites for your next side hustle, how to maximize your survey earnings, and how to avoid scams.
How to Earn Money Through User Testing
Learn how to become user tester, how much you can earn, top platforms for user testing, and how to avoid scams.

Ask a question

Click here to cancel reply.

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

How to buy Kraig Biocraft Laboratories Inc (KBLB) stock when it goes public

Here's everything we know so far about the Kraig Biocraft Laboratories Inc IPO.

What we know about the Kraig Biocraft Laboratories Inc IPO

How to buy Kraig Biocraft Laboratories Inc stock when it starts trading